Price$1.83-1.21 (-39.80%)
2026-03-172026-06-18
News · 26 weeks43-50%
2025-12-282026-06-21
Mix2390d
- SEC Filings9(39%)
- Insider8(35%)
- Earnings3(13%)
- Other2(9%)
- Offering1(4%)
Latest news
25 items- SECSEC Form S-8 filed by Imunon Inc.S-8 - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 8-K filed by Imunon Inc.8-K - Imunon, Inc. (0000749647) (Filer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,593 shares, increasing direct ownership by 44% to 5,235 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Announces Up to $10 Million Cash FinancingIncludes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured pr
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 3,484 shares, increasing direct ownership by 66% to 8,749 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Pellizzari Christine A was granted 5,557 shares, increasing direct ownership by 215% to 8,142 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Dentzer James E was granted 11,148 shares, increasing direct ownership by 292% to 14,963 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Braun Donald P was granted 5,011 shares, increasing direct ownership by 116% to 9,319 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Fritz Frederick J. was granted 10,330 shares, increasing direct ownership by 274% to 14,097 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 1,491 shares, increasing direct ownership by 69% to 3,642 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECSEC Form 10-Q filed by Imunon Inc.10-Q - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports First Quarter 2026 Financial Results and Provides Business UpdateIMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin
- PRIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U
- SECImunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form DEF 14A filed by Imunon Inc.DEF 14A - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 10-K filed by Imunon Inc.10-K - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 StudyIMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother
- PRIMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian CancerThe increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final cl
- PRIMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1
- SECImunon Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 424B5 filed by Imunon Inc.424B5 - Imunon, Inc. (0000749647) (Filer)
IMNN FAQ
4 questionsWhere does IMNN stock trade?
Imunon Inc. (IMNN) is listed on NASDAQ.What sector and industry is IMNN in?
Imunon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IMNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMNN side-by-side with any of them on Quantisnow.How can I track IMNN on Quantisnow?
Quantisnow aggregates Imunon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNN to receive live email and push alerts on every new disclosure.